SCHEMBL20620191

SCHEMBL20620191

O=C1/C(=N\O)CCN(Cc2ccccc2)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
ALDH3A1 P30838 3/20 0.46
ALDH2 P05091 1/20 0.46
CHRM1 P11229 1/20 0.46
CES1 P23141 1/20 0.46
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
BRD4 O60885 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.41
DHPS P49366 1/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CACNA1G O43497 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL426981 0.78 KMT2A (0.54) ALDH1A1ALDH3A1ALDH2CHRM1CES1
SCHEMBL9306554 0.76 DDB1 (0.48) DDB1CRBNL3MBTL1DHPSCYP2C19
SCHEMBL9306550 0.76 DDB1 (0.48) DDB1CRBNL3MBTL1DHPSCYP2C19
SCHEMBL20622382 0.76 ALDH1A1 (0.46) ALDH1A1ALDH3A1CES1L3MBTL1CYP2C19
SCHEMBL13273475 0.76 ALDH1A1 (0.46) ALDH1A1ALDH3A1CES1L3MBTL1CYP2C19
SCHEMBL20622393 0.73 L3MBTL1 (0.58) ALDH1A1ALDH3A1ALDH2CHRM1CES1
SCHEMBL4130800 0.70 ACHE (0.49) ALDH1A1DDB1CRBNL3MBTL1DHPS
SCHEMBL4130797 0.70 ACHE (0.49) ALDH1A1DDB1CRBNL3MBTL1DHPS
SCHEMBL34470360 0.70 BRD4 (0.36) ALDH1A1DDB1CRBNBRD4L3MBTL1
SCHEMBL19892964 0.70 BRD4 (0.39) ALDH1A1DDB1CRBNBRD4DHPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091501-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-08-17 US disclosed
WO-2019006295-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091501-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 ALDH1A1 721/4885ALDH3A1 329/4885ALDH2 1634/4885
US-20190002479-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 ALDH1A1 721/4885ALDH3A1 329/4885ALDH2 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.